The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000551392p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
9/04/2026
Date registered
Help: Date registered
1/05/2026
Date last updated
Help: Date last updated
1/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Home platelet transfusion in patients with blood cancers
Scientific title
A feasibility study of home platelet transfusion in patients with haematological malignancy
Additional trial identifiers [1] 316991 0
nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Blood transfusion 341464 0
Blood cancer 341465 0
Condition category
Condition code
Cancer 337529 337529 0 0
Leukaemia - Acute leukaemia
Cancer 337530 337530 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 337531 337531 0 0
Myeloma

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Platelet (blood product) transfusion will be given by nursing staff to select patients with haematological malignancy (blood cancer) in the patient’s own home. This will occur up to 3 times per week for up to 12 weeks and does not affect other treatments the patient may be receiving. The platelet transfusion is the same as standard of care (usually given in the outpatient centre or hospital ward) - 1 unit of platelets given over 15-30 minutes. The platelet transfusion will be given to patients on the trial as per the clinical need (based on measured platelet count taken routinely the day prior, or presence of bleeding) and this intervention will be administered at the next clinically appropriate scheduled transfusion.
Intervention code [1] 333740 0
Treatment: Other
Description of the comparator or control
The comparison is to usual care. This will be identical to the intervention, but a different location: intervention is in a patients' home, usual care is given in the hospital. The patients will be their own control.
Control group
Active

Outcomes
Primary outcome [1] 345027 0
Demonstrate the feasibility of home platelet transfusion for patients with blood cancers in the Australian public healthcare setting. Descriptive analysis of: 1. Ability to recruit patients 2. Number of planned transfusions completed
Timepoint [1] 345027 0
At 12 weeks post enrollment commencement
Secondary outcome [1] 460221 0
Analysis of safety events
Timepoint [1] 460221 0
At 12 weeks post treatment commencement
Secondary outcome [2] 460222 0
Determine whether home transfusion is acceptable to patients, caregivers and clinicians. This will be assessed as a composite outcome.
Timepoint [2] 460222 0
During the trial or within 3 months of trial conclusion
Secondary outcome [3] 460589 0
Descriptive estimate of costs involved in the transfusion
Timepoint [3] 460589 0
At 12 weeks post treatment commencement

Eligibility
Key inclusion criteria
Age 18 years or over
Diagnosis of a haematological malignancy (most commonly Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Lymphoma or Myeloma)
Transfusion dependence (currently requiring at least one unit of platelet transfusion per fortnight)
Eligible for admission to Hospital in the Home (as per current local guidelines and policies)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Previous severe haemolytic or allergic reactions
Unstable cardiorespiratory status (cardiac arrest or myocardial infarction within 12 months, ejection fraction <40%, NYHA class II-IV heart failure)
Difficult to obtain intravenous access and does not have an existing or planned central venous access device (CVAD) (e.g. PICC line)
No responsible caregiver, inappropriate home environment
Treating clinician deems study is not in the best interest of the patient

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321588 0
University
Name [1] 321588 0
Monash University
Country [1] 321588 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Country
Australia
Secondary sponsor category [1] 324390 0
None
Name [1] 324390 0
Address [1] 324390 0
Country [1] 324390 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320115 0
Monash Health Human Research Ethics Committee A
Ethics committee address [1] 320115 0
Ethics committee country [1] 320115 0
Australia
Date submitted for ethics approval [1] 320115 0
21/01/2026
Approval date [1] 320115 0
Ethics approval number [1] 320115 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149486 0
Dr Briony Shaw
Address 149486 0
School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd Melbourne 3004
Country 149486 0
Australia
Phone 149486 0
+61 3 990 30114
Fax 149486 0
Email 149486 0
Contact person for public queries
Name 149487 0
Briony Shaw
Address 149487 0
School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd Melbourne 3004
Country 149487 0
Australia
Phone 149487 0
+61 3 95946666
Fax 149487 0
Email 149487 0
Contact person for scientific queries
Name 149488 0
Briony Shaw
Address 149488 0
School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd Melbourne 3004
Country 149488 0
Australia
Phone 149488 0
+61 3 95946666
Fax 149488 0
Email 149488 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.